Gilead licenses anti-HIV drug to generic drugmakers

By Agence France-Presse

Oct 04, 2024 12:06 am

WASHINGTON, D.C. — United States pharmaceutical giant Gilead said on Wednesday it had signed licensing deals with six generic drugmakers to produce and sell its human immunodeficiency virus (HIV) prevention medicine in lower-income countries.

The announcement comes shortly after Gilead faced pressure to open lenacapavir to a patent pool that would allow generics to be sold under license in those countries.

Already have an active account? Log in here to continue reading.
Or
Subscribe to the Premium Subscription plan to access this subscriber-exclusive article.

Related Articles

Trump taps 'Apprentice' producer as special envoy to UK

Trump threatens to take back control of Panama Canal

Winter is hitting Gaza and many Palestinians have little protection from the cold

Two US Navy pilots shot down over Red Sea in apparent 'friendly fire' incident, US military says

2 dead, 60 hurt in German car attack

16 Israelis wounded by Yemen missile

Funding difficulties spell gloom for workers